Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Cytoreductive nephrectomy in mRCC

Bradley McGregor • 2 Jun 2019
ASCO 2019
Kidney Cancer

Here, Bradley McGregor, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the role of cytoreductive nephrectomy in metastatic renal cell carcinoma (mRCC). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Bradley McGregor

4:21
Sacituzumab govitecan plus enfortumab vedotin for treatment of advanced urothelial cancer
Bradley McGregor • 22 Oct 2023
4:21
Sacituzumab govitecan plus enfortumab vedotin in advanced urothelial cancer
Bradley McGregor • 23 Oct 2023
1:56
Nivolumab and ipilimumab for advanced BCVH
Bradley McGregor • 2 Jun 2019
2:09
Enfortumab vedotin for bladder cancer
Bradley McGregor • 2 Jun 2019

Related Videos

2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:52
LITESPARK-004: ESA use in VHL disease-associated RCC
Benjamin Maughan • 26 Jan 2024
3:04
Evaluating the role of radiotherapy in primary and metastatic RCC
Sophia Kamran • 26 Jan 2024
2:14
Managing renal cell carcinoma after progressing on checkpoint inhibitors
David Braun • 14 Feb 2024
The content of VJOncology is intended for healthcare professionals